Literature DB >> 30280307

Histone variants: critical determinants in tumour heterogeneity.

Tao Wang1,2, Florent Chuffart1, Ekaterina Bourova-Flin1, Jin Wang2, Jianqing Mi2, Sophie Rousseaux1, Saadi Khochbin3.   

Abstract

Malignant cell transformation could be considered as a series of cell reprogramming events driven by oncogenic transcription factors and upstream signalling pathways. Chromatin plasticity and dynamics are critical determinants in the control of cell reprograming. An increase in chromatin dynamics could therefore constitute an essential step in driving oncogenesis and in generating tumour cell heterogeneity, which is indispensable for the selection of aggressive properties, including the ability of cells to disseminate and acquire resistance to treatments. Histone supply and dosage, as well as histone variants, are the best-known regulators of chromatin dynamics. By facilitating cell reprogramming, histone under-dosage and histone variants should also be crucial in cell transformation and tumour metastasis. Here we summarize and discuss our knowledge of the role of histone supply and histone variants in chromatin dynamics and their ability to enhance oncogenic cell reprogramming and tumour heterogeneity.

Entities:  

Keywords:  H1.0; H1F0; H1T; TH2A; TH2B; cancer-testis; linker histones

Year:  2019        PMID: 30280307     DOI: 10.1007/s11684-018-0667-3

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  7 in total

Review 1.  Solid tumours hijack the histone variant network.

Authors:  Flávia G Ghiraldini; Dan Filipescu; Emily Bernstein
Journal:  Nat Rev Cancer       Date:  2021-02-10       Impact factor: 60.716

Review 2.  Epigenetic regulation of anterior segment diseases and potential therapeutics.

Authors:  Eric Chen; Kelley Bohm; Mark Rosenblatt; Kai Kang
Journal:  Ocul Surf       Date:  2020-04-25       Impact factor: 5.033

Review 3.  Histone Variants: Guardians of Genome Integrity.

Authors:  Juliette Ferrand; Beatrice Rondinelli; Sophie E Polo
Journal:  Cells       Date:  2020-11-05       Impact factor: 6.600

4.  Proteomic Profiling of Saliva and Tears in Radiated Head and Neck Cancer Patients as Compared to Primary Sjögren's Syndrome Patients.

Authors:  Håvard Hynne; Lara A Aqrawi; Janicke Liaaen Jensen; Bernd Thiede; Øyvind Palm; Cecilie Delphin Amdal; Kristine Løken Westgaard; Bente Brokstad Herlofson; Tor P Utheim; Hilde Kanli Galtung
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

5.  H2A.B is a cancer/testis factor involved in the activation of ribosome biogenesis in Hodgkin lymphoma.

Authors:  Xuanzhao Jiang; Jiayu Wen; Elizabeth Paver; Yu-Huan Wu; Gege Sun; Amanda Bullman; Jane E Dahlstrom; David J Tremethick; Tatiana A Soboleva
Journal:  EMBO Rep       Date:  2021-07-19       Impact factor: 9.071

6.  Quantitative proteome analysis of Merkel cell carcinoma cell lines using SILAC.

Authors:  Ulana Kotowski; Boban M Erović; Julia Schnöll; Victoria Stanek; Stefan Janik; Martin Steurer; Goran Mitulović
Journal:  Clin Proteomics       Date:  2019-12-19       Impact factor: 3.988

7.  Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity.

Authors:  Paul T Winnard; Farhad Vesuna; Sankar Muthukumar; Venu Raman
Journal:  PLoS One       Date:  2020-11-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.